Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Mazindol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NLS Launches Preclinical Program for Mazindol in Fentanyl Dependence
    NLS Launches Preclinical Program for Mazindol in Fentanyl Dependence

    28 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nls-pharmaceutics-announces-the-launch-of-a-preclinical-program-for-mazindol-er-in-the-treatment-of-fentanyl-dependence-302361724.html

    PR NEWSWIRE
    28 Jan 2025
    Share Share
    NLS Secures Patent In Japan For Mazindol ER For Heroin Dependence
    NLS Secures Patent In Japan For Mazindol ER For Heroin Dependence

    21 Oct 2024

    // ACCESSWIRE

    https://www.accesswire.com/933330/nls-pharmaceutics-secures-key-patent-in-japan-for-mazindol-er-in-the-treatment-of-heroin-dependence

    ACCESSWIRE
    21 Oct 2024
    Share Share
    NLS Pharma: Mazindol Neuroprotection In Narcolepsy Rat Model
    NLS Pharma: Mazindol Neuroprotection In Narcolepsy Rat Model

    28 May 2024

    // ACCESSWIRE

    https://www.accesswire.com/867511/nls-pharmaceutics-reports-positive-results-from-study-ko-874-on-mazindols-neuroprotective-effects-in-narcoleptic-like-rat-model

    ACCESSWIRE
    28 May 2024
    Share Share
    NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER
    NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER

    03 Jul 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=765143&lang=en

    ACCESSWIRE
    03 Jul 2023
    Share Share
    NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450
    NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450

    14 Jun 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=761224&lang=en

    ACCESSWIRE
    14 Jun 2023
    Share Share
    NLS Receives Green Light from the USFDA to Proceed with Ph3 Program (AMAZE)
    NLS Receives Green Light from the USFDA to Proceed with Ph3 Program (AMAZE)

    02 May 2023

    // BUSINESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=752432&lang=en

    BUSINESSWIRE
    02 May 2023
    Share Share